Togha Mansooreh, Ashrafian Hossein, Tajik Parvin
Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Iran.
Headache. 2006 Mar;46(3):498-502. doi: 10.1111/j.1526-4610.2006.00381.x.
To assess the effectiveness and safety of cinnarizine as a migraine-preventive therapy.
Sixty patients with more than 2 migraine headache attacks during a 4-week baseline entered the study and received a 25-mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated.
The mean reduction in 4-week migraine headache rate was 4.6 +/- 2.2 from the baseline of 6.2 +/- 2.2 after 14 weeks of treatment, which was statistically significant (P < 0.001). Percent reduction in 4-week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration (P < 0.001) and severity (P < 0.001) was also noted. No serious adverse events were observed in this series of patient.
Cinnarizine is an efficacious and well-tolerated prophylactic antimigraine medication, which has early onset effectiveness.
评估桂利嗪作为偏头痛预防性治疗的有效性和安全性。
60例在4周基线期内偏头痛发作超过2次的患者进入本研究，在最初3天每天服用2次25毫克桂利嗪片剂，之后每天服用3次。在第2、6、10和14周对他们进行评估。4周偏头痛头痛率相对于基线的降低是主要疗效变量。还评估了偏头痛发作持续时间和严重程度的降低情况。
治疗14周后，4周偏头痛头痛率从基线的6.2±2.2降至4.6±2.2，具有统计学意义（P<0.001）。治疗2周后4周偏头痛发作频率降低百分比为35%，6周后为74%，10周后为74%，14周后为75%。发作持续时间（P<0.001）和严重程度（P<0.001）也有显著降低。在这一系列患者中未观察到严重不良事件。
桂利嗪是一种有效且耐受性良好的预防性抗偏头痛药物，起效较早。
